Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Resources

Neonatal Jaundice: When to Worry?

: Live Program
: 1.5 AMA PRA Category 1 Credit(s)™
Target Audience
: Healthcare providers who care for patients with neonatal jaundice
Expiration Date
: 05/06/2018

Read the content below to launch the activity

Register now!

Please join us for an Industry-Sponsored Symposium at PAS 2018
Neonatal Jaundice: When to Worry?
This activity is supported by an independent educational grant from Mallinckrodt Pharmaceuticals

Sunday, May 6, 2018
Breakfast: 5:30 am – 6:15 am
Scientific Program: 6:15 am – 7:45 am

Ballroom B, Lobby Level
InterContinental Toronto Centre Hotel
225 Front Street West
Toronto, ON, Canada

Activity Overview

Normal newborn conditions can contribute to elevated bilirubin levels, resulting in physiologic jaundice. Although neonatal jaundice is a frequent postpartum event, in some neonates with major risk factors it may be a marker of potentially severe hyperbilirubinemia. Because unconjugated bilirubin can diffuse passively across the blood-brain barrier, it can cause bilirubin neurotoxicity, damaging specific regions of the brain. Detection of early hyperbilirubinemia is critical to the prevention of irreversible effects of chronic bilirubin encephalopathy.

The objective of this CME-certified activity is to disseminate knowledge of newborn jaundice to prevent kernicterus. It will help clinicians identify and determine the causes of jaundice in the newborn, intervene when appropriate, and prevent acute or chronic bilirubin-associated neurotoxicity. Experts will address the differential diagnosis of neonatal jaundice and risk factors for severe hyperbilirubinemia. The faculty will also discuss the AAP Clinical Practice Guideline and more recent updated management recommendations, as well as future directions for the prevention and treatment of severe hyperbilirubinemia.

Educational Objectives

Upon completion of this activity, participants should be able to:

1.  Discuss the epidemiology of neonatal jaundice and the effects of bilirubin-associated neurotoxicity in the newborn
2.  Distinguish between physiologic jaundice and pathologic jaundice in the newborn
3.  Perform a differential diagnosis of neonatal jaundice and describe the factors that place a newborn at risk for developing severe hyperbilirubinemia
4.  Apply the key elements of the AAP Clinical Practice Guideline for the management of hyperbilirubinemia in the newborn infant
5.  Discuss future directions for the prevention and treatment of severe hyperbilirubinemia


Vinod K. Bhutani, MD, FAAP
Program Chair
Professor of Pediatrics (Neonatology)
Stanford University School of Medicine
Lucile Packard Children’s Hospital
Stanford, CA

Robert D. Christensen, MD
Director, Neonatology Research
Intermountain Healthcare
Professor, Neonatology and Hematology/Oncology
University of Utah Health
Salt Lake City, UT

Thor Willy Ruud Hansen, MD, PhD, MHA, FAAP
Professor of Pediatrics (Emeritus)
Institute of Clinical Medicine
University of Oslo
Director of Clinical Ethics
Oslo University Hospital
Oslo, Norway

Bryon Lauer, MD, FAAP
Assistant Professor
Department of Pediatrics
Drexel University College of Medicine
Philadelphia, PA

Jon F. Watchko, MD
Professor of Pediatrics, Obstetrics, Gynecology and Reproductive Sciences
Division of Newborn Medicine
Department of Pediatrics
University of Pittsburgh School of Medicine
Magee-Womens Hospital
Children’s Hospital of Pittsburgh
Magee-Womens Research Institute
Pittsburgh, PA